Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-11-27
2007-11-27
Woitach, Joseph (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S071200, C435S041000, C435S070100
Reexamination Certificate
active
10764201
ABSTRACT:
The present invention relates to non-vaccinal and non-pharmacologic compositions and methods for controlling complex retroviral infections. In particular, the present invention provides transgenic animals expressing a transdominant negative Rex gene product that inhibits retroviral replication.
REFERENCES:
patent: 5871958 (1999-02-01), Cullen
patent: 6162898 (2000-12-01), Cullen
patent: 2003/0083290 (2003-05-01), Kingsman et al.
patent: 0406557 (1990-05-01), None
Oroszlan et al., Primary structure analysis of the major internal protein p24 of human type C T-cell leukemia virus. Proc Natl Acad Sci U S A. Feb. 1982;79(4):1291-4.
Pollari, F.L., et al., “Effects of bovine leukemia virus infection on production and reproduction in dairy cattle,” Can. J. Vet. Res., 56(4):289-95 (1992).
Hidaka et al., “Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins,” EMBO J 7:519 (1988).
Malim, M.H., et al., “Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes,” Nature, 335:181 (1988).
Rimsky, L., et al., “Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein,” Nature, 335:738 (1988).
Green, P.L., et al., The Retroviridae, p. 227-311, vol. 3, Eds. Levy, J.A., Plenum Press, New York, N.Y., (1994).
Ghysdael, K., et al., “Bovine leukemia virus,” Current Topics in Microbiology and Immunology 112:1 (1984) Gree, P.L., The Retroviridae, p. 227-311, vol. 3, Eds. Levy, J.A., Plenum Press, New York, N.Y., (1994).
Orlik, O., and Splitter G.A., “Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env- encoded BLV proteins,” J. Virol., 70(11):7584 (1996).
Elovaara, I., et al., “High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease,” J. Exp. Med., 177:1567 (1993).
Lassauzet, ML, et al., “Factors associated with transmission of bovine leukemia virus by contact in cows on a California dairy,” Amer. J. Epidemiol, 133:164-76 (1991).
Lassauzet, M.L., et al., “Effect of brucellosis vaccination and dehorning on transmission of bovine leukemia virus in heifers on a California dairy,” Can. J. Vet. Res. 54:184-189 (1990).
Buxton, B.A., and Schultz, R.D., “Factors affecting the infectivity of lymphocytes from cattle with bovine leukosis virus,” Can. J. Comp. Med., 48(4):365-369 (1984).
Herskowitz, I., Nature 329:317 (1987).
Hope, I.A., and Struhl, K., “Functional dissection of a eukaryotic transcriptional activator protein, GCN4 of yeast,” Cell 46:885 (1986).
Gentz, R., et al., “Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains,” Science 243:1695 (1989).
Triezenberg, S.J., et al., Gen. & Devel., 2:718 (1988).
Friedman A.D., et al., “Functional dissection of VP16, tha trans-activator of herpes simplex virus immediate early gene expression,” Nature, 335:452 (1988).
Wachsman, V., et al., “HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes,” Science 235:674 (1987).
Green, M., et al., “Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression,” Cell 58:215 (1989).
Trono, D., et al., “HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus,” Cell 59:113 (1989).
Orlik, O., and Splitter G.A., “Optimization of lymphocyte proliferation assay for cells with high spontaneous proliferation in vitro: CD4+ T cell proliferation in bovine leukemia virus infected animals with persistent lymphocytosis,” J. Immunol. Methods 199:159 (1996).
Kimata, J.J., et al., “The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway,” J. Virol., 67:3134 (1993).
Boris-Lawrie et al., “In vivo study of genetically simplified bovine leukemia virus derivatives that lack tax and rex,” J Virol 71(2):1514-20 (1997).
Gatei M.H., et al., “Experimental infection of sheep with bovine leukemia virus: infectivity of blood, nasal and saliva secretions,” Zentralbl Veterinarmed, (B) 36(9):652-60 (1989).
Bremel Robert D.
Choi Eun-A
Eakle Kurt
Homan Jane
Hope Thomas
Casimir Jones S.C.
ioGenetics, LLC
Leavitt Maria
Woitach Joseph
LandOfFree
Transgenic animals expressing transdominant negative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic animals expressing transdominant negative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic animals expressing transdominant negative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3841353